BioScrip (NASDAQ:BIOS) Shares Gap Up to $3.07

BioScrip Inc (NASDAQ:BIOS) gapped up before the market opened on Thursday . The stock had previously closed at $3.07, but opened at $3.07. BioScrip shares last traded at $3.17, with a volume of 117,176 shares traded.

Several equities analysts have recently weighed in on BIOS shares. Zacks Investment Research lowered shares of BioScrip from a “hold” rating to a “sell” rating and set a $4.00 target price for the company. in a report on Monday, November 18th. BidaskClub downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a report on Thursday. SunTrust Banks raised their price target on shares of BioScrip from $3.25 to $4.25 and gave the company a “buy” rating in a research report on Friday, September 20th. ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Monday, November 11th. Finally, Canaccord Genuity lifted their price objective on shares of BioScrip from $3.50 to $4.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. BioScrip presently has an average rating of “Hold” and a consensus target price of $4.79.

The company has a quick ratio of 1.36, a current ratio of 1.71 and a debt-to-equity ratio of 1.43. The business has a 50-day simple moving average of $3.42 and a 200-day simple moving average of $2.98. The company has a market cap of $2.15 billion, a PE ratio of -6.56 and a beta of 0.44.

Several institutional investors have recently bought and sold shares of BIOS. Venor Capital Management LP lifted its stake in BioScrip by 3.4% in the 2nd quarter. Venor Capital Management LP now owns 12,333,605 shares of the company’s stock valued at $32,067,000 after buying an additional 400,000 shares in the last quarter. Gabelli Funds LLC boosted its stake in shares of BioScrip by 6.0% in the second quarter. Gabelli Funds LLC now owns 7,168,041 shares of the company’s stock worth $18,637,000 after acquiring an additional 407,422 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of BioScrip by 5.3% in the second quarter. Vanguard Group Inc. now owns 6,551,808 shares of the company’s stock worth $17,034,000 after acquiring an additional 332,385 shares during the last quarter. Rothschild & Co. Asset Management US Inc. increased its position in shares of BioScrip by 1.6% during the second quarter. Rothschild & Co. Asset Management US Inc. now owns 3,874,113 shares of the company’s stock worth $10,073,000 after purchasing an additional 61,642 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of BioScrip by 2.4% during the second quarter. Northern Trust Corp now owns 1,486,282 shares of the company’s stock worth $3,864,000 after purchasing an additional 35,116 shares in the last quarter. Institutional investors and hedge funds own 15.49% of the company’s stock.

About BioScrip (NASDAQ:BIOS)

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

See Also: What are benefits of a growth and income fund?

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.